Company Analysis Aurobindo Pharma Limited
1. Summary
Disadvantages
- Price (1527.35 βΉ) is higher than fair price (639.74 βΉ)
- Dividends (0.7306%) are below the sector average (12.08%).
- The stock's return over the last year (16.6%) is lower than the sector average (39.02%).
- Current debt level 14.01% has increased over 5 years from 0%.
- The company's current efficiency (ROE=11.2%) is lower than the sector average (ROE=17.13%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Aurobindo Pharma Limited | Index | ||
|---|---|---|---|
| 7 days | 2.4% | -1.8% | 0.1% |
| 90 days | -15.9% | 0.6% | -4% |
| 1 year | 16.6% | 39% | 8.6% |
AUROPHARMA vs Sector: Aurobindo Pharma Limited has significantly underperformed the "" sector by -22.43% over the past year.
AUROPHARMA vs Market: Aurobindo Pharma Limited has outperformed the market by 8.03% over the past year.
Stable price: AUROPHARMA is not significantly more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AUROPHARMA with weekly volatility of 0.3192% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1527.35 βΉ) is higher than the fair price (639.74 βΉ).
Price is higher than fair: The current price (1527.35 βΉ) is 58.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.84) is lower than that of the sector as a whole (45.31).
P/E vs Market: The company's P/E (18.84) is lower than that of the market as a whole (43.66).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2) is lower than that of the sector as a whole (6.25).
P/BV vs Market: The company's P/BV (2) is lower than that of the market as a whole (6.15).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.08) is lower than that of the sector as a whole (5.02).
P/S vs Market: The company's P/S indicator (2.08) is lower than that of the market as a whole (8.67).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (7.61) is lower than that of the sector as a whole (13.54).
EV/Ebitda vs Market: The company's EV/Ebitda (7.61) is lower than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 2.42% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (2.42%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-37.97%).
5.4. ROE
ROE vs Sector: The company's ROE (11.2%) is lower than that of the sector as a whole (17.13%).
ROE vs Market: The company's ROE (11.2%) is higher than that of the market as a whole (-0.3088%).
5.5. ROA
ROA vs Sector: The company's ROA (7.47%) is lower than that of the sector as a whole (10.35%).
ROA vs Market: The company's ROA (7.47%) is lower than that of the market as a whole (7.53%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (6.91%) is lower than that of the sector as a whole (10.89%).
ROIC vs Market: The company's ROIC (6.91%) is lower than that of the market as a whole (16.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.7306% is below the average for the sector '12.08%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.7306% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 0.7306% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (8.31%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
